Automating Gastroenterology ePA via NCPDP SCRIPT

Klivira streamlines **gastroenterology ePA via NCPDP SCRIPT** to accelerate patient access to critical biologic and specialty medications, reducing administrative burden for GI practices.

Gastroenterology practices face a significant prior authorization burden, particularly for high-cost biologics and specialty drugs often managed under the pharmacy benefit. Manual processes for electronic prior authorization (ePA) via NCPDP SCRIPT can lead to delays, increased denial rates, and staff burnout. Klivira provides a robust solution to automate this complex workflow, ensuring timely approvals and optimizing revenue cycles.

The Challenge of Gastroenterology ePA for Pharmacy Benefits

GI practices frequently prescribe self-administered biologics (e.g., Humira, Stelara, Skyrizi, Entyvio) and specialty drugs (e.g., Viberzi, Linzess) for chronic conditions like IBD, Hepatitis C, and functional GI disorders. These high-cost medications almost universally trigger prior authorization, often requiring submission via the NCPDP SCRIPT standard for pharmacy benefit claims. The volume and complexity of these submissions, coupled with specific payer requirements, strain administrative resources.

Key Pharmacy Benefit PA Triggers in Gastroenterology

IBD Biologics: Self-administered TNF inhibitors (adalimumab/Humira), integrin inhibitors (vedolizumab/Entyvio), IL-12/23 inhibitors (ustekinumab/Stelara, risankizumab/Skyrizi), JAK inhibitors (tofacitinib/Xeljanz, upadacitinib/Rinvoq), S1P modulators (ozanimod/Zeposia, etrasimod/Velsipity).
Hepatitis C Direct-Acting Antivirals (DAAs): sofosbuvir-velpatasvir (Epclusa), glecaprevir-pibrentasvir (Mavyret).
Specialty Drugs for Functional GI Disorders: eluxadoline (Viberzi), prucalopride (Motegrife), linaclotide (Linzess), plecanatide (Trulance).
Other high-cost oral medications requiring pharmacy benefit prior authorization.

Navigating Payer Requirements and Clinical Guidelines

Successful ePA submissions for GI medications demand meticulous adherence to payer-specific medical necessity criteria, which are often informed by clinical guidelines from bodies like the American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), and American Association for the Study of Liver Diseases (AASLD). Documentation requirements include disease severity scores (e.g., Mayo score for UC, CDAI for Crohn's), proof of prior conventional therapy, TB/hepatitis screening for biologics, and genotype/fibrosis staging for Hep C DAAs.

EMR Integration and Payer Connectivity for Seamless Workflow

Klivira integrates directly with leading EMR systems via SMART on FHIR, extracting relevant clinical data points required for NCPDP SCRIPT ePA submissions. This eliminates manual data entry and reduces errors. Our platform connects to a vast network of payers and PBMs through the NCPDP SCRIPT standard, ensuring that prior authorization requests for pharmacy benefit drugs are submitted through the correct electronic channels, including those mandated by CMS ePA rules.

Addressing Common GI ePA Denial Drivers

Denials for gastroenterology ePA via NCPDP SCRIPT frequently stem from issues such as non-compliance with step therapy requirements for IBD biologics, missing documentation of disease severity or screening tests, and failure to classify treatment-naive versus treatment-experienced patients accurately for both IBD and Hep C DAAs. Klivira's logic engine is designed to proactively identify and address these common pitfalls before submission, improving first-pass approval rates.

Klivira's Differentiated Approach to GI Pharmacy PA

Klivira automates the complex nuances of GI pharmacy prior authorizations. Our system incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologics, automatically classifies treatment status from EMR medication histories, and manages periodic re-authorization workflows for chronic treatments. By intelligently routing pharmacy benefit requests via NCPDP SCRIPT and adapting to payer-specific biosimilar substitution policies, Klivira significantly reduces the administrative burden and accelerates patient access to essential GI medications.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for GI biologics?

Klivira's platform is designed to identify the appropriate benefit channel. For self-administered GI biologics falling under the pharmacy benefit, our system ensures the prior authorization request is accurately formatted and submitted via the NCPDP SCRIPT standard to the relevant PBM or payer.

Can Klivira help with re-authorizations for chronic GI conditions like IBD?

Yes, Klivira automates the workflow for periodic re-authorization of chronic-treatment IBD biologics. Our system tracks re-authorization cadences and prompts for necessary documentation, ensuring continuous coverage and minimizing treatment interruptions for patients.

What specific GI drugs does Klivira support for ePA via NCPDP SCRIPT?

Klivira supports ePA for a wide range of pharmacy benefit GI drugs, including IBD biologics like Humira, Stelara, Skyrizi, and Entyvio; Hepatitis C DAAs such as Epclusa and Mavyret; and specialty functional GI drugs like Viberzi, Motegrife, Linzess, and Trulance.

How does Klivira ensure compliance with step therapy for GI biologics?

Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic. This allows our system to identify when conventional therapies or biosimilars must be tried first, guiding the prior authorization process to align with payer policies and reduce denials related to step therapy non-compliance.

What EMR systems does Klivira integrate with for GI ePA?

Klivira integrates with leading EMR systems via SMART on FHIR. This allows for direct extraction of clinical data, medication histories, and diagnostic results relevant to GI prior authorizations, streamlining the data collection process for NCPDP SCRIPT submissions.